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Abstract
Background—Elevated total serum alkaline phosphatase (ALP) levels have been associated 
with mortality in the general population and in dialysis patients.
Study Design—Retrospective cohort study.
Setting & Participants—28,678 patients with chronic kidney disease (CKD) stages 3 and 4 
(estimated glomerular filtration rate [eGFR], 15–59 ml/min/1.73 m2) were identified using the 
Cleveland Clinic Chronic Kidney Disease Registry. CKD was defined as two eGFR values <60 
ml/min/1.73 m2 drawn >90 days apart using the Chronic Kidney Disease Epidemiology 
Collaboration creatinine equation.
Predictor—ALP levels measured using the calorimetric assay was examined as quartiles 
(quartile 1, <66 U/L; Q2, 66–81 U/L; Q3, 82–101 U/L; and Q4, ≥102 U/L) and as a continuous 
measure.
Outcomes & Measurements—All-cause mortality and ESRD were ascertained using the 
Social Security Death Index and US Renal Data System.
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Results—After a median follow up of 2.2 years, 588 patients progressed to ESRD and 4,755 
died. There was a graded increase in the risk for mortality with higher ALP quartiles (Q2, Q3, Q4) 
when compared to the reference quartile (Q1) after adjusting for demographics, comorbid 
conditions, use of relevant medications and liver function tests. The highest quartile of ALP was 
associated with a hazard ratio for ESRD of 1.38 (95% CI, 1.09–1.76). Each 1-standard deviation 
(42.7 U/L) higher ALP level was associated with 15% (95% CI, 1.09–1.22) and 16% (95% CI, 
1.14–1.18) increased risk of ESRD and mortality respectively.
Limitations—Single center observational study, lack complete data including PTH for all study 
participants and attrition bias.
Conclusions—Higher serum ALP levels in CKD stages 3–4 were independently associated with 
all-cause mortality and ESRD.
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Elevated serum alkaline phosphatase (ALP) contributes to the development and progression 
of vascular calcification1,2. Studies conducted in general population have shown 
independent associations between ALP and increased risk of cardiovascular events, 
hospitalization and death3, 4. Patients with CKD have higher ALP due to disturbances in the 
bone mineral disease which may contribute to the higher cardiovascular burden seen in this 
population. Previous studies have reported that an elevated ALP is associated with increased 
risk of coronary artery calcification and mortality in maintenance hemodialysis patients5–7. 
Recent studies have shown that in selective non-dialysis dependent CKD populations such 
as African Americans and males, higher ALP levels are associated with increased risk for 
all-cause mortality8, 9.
The recently published Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 
recommend that ALP be measured annually in patients with CKD stages 4 and 5 as an 
adjunct test when monitoring medical therapy or to assess for active bone turnover in the 
presence of secondary hyperparathyroidism10. While the previous studies examined the 
associations of ALP with mortality, its relationship with progression of kidney disease is 
unclear. We hypothesized that higher ALP levels are independently associated with an 
increased risk for ESRD and death in those with CKD stages 3 and 4 even after accounting 
for competing risks in this population. Therefore, we evaluated the relationship between 
ALP and ESRD and all-cause mortality in a large, diverse population withCKD stages 3–4 
followed in our health care system.
Methods
Study Population
We conducted an analysis using our pre-existing electronic health record (EHR)-based CKD 
registry. The development and validation of this registry at Cleveland Clinic have been 
described in detail elsewhere11. Patients who met the following criteria between January 1, 
2005 and September 15, 2009 were included in the study population: 1) had at least one 
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face-to-face outpatient encounter with a Cleveland Clinic health care provider, 2) had two 
eGFR values <60 ml/min/1.73 m2 (using the CKD Epidemiology Collaboration [CKD-EPI] 
creatinine equation) more than 90 days apart and 3) had ALP measured between the first and 
second eGFR <60 ml/min/1.73 m2 indicating CKD as an outpatient using a standard assay in 
our health system12. Patients aged <18 years old, who had eGFR <15 ml/min/1.73 m2, and 
those who were diagnosed with ESRD needing dialysis or kidney transplantation prior to 
CKD diagnosis were excluded.
Definitions and Outcome Measures
Kidney function—We applied the 2009 CKD-EPI creatinine equation to patients who had 
two outpatient serum creatinine levels between January 1, 2005 and September 15, 2009 in 
our health system to calculate eGFR. All creatinine measurements were performed by the 
modified kinetic Jaffe reaction, using a Hitachi 747-200 Chemistry Analyzer (1996 to 2001) 
or a Hitachi D 2400 Modular Chemistry Analyzer thereafter (Roche Diagnostics, 
Indianapolis, IN) in our laboratory. All serum creatinine assays were standardized to 
isotope-dilution mass spectrometry (IDMS). CKD was defined according to the CKD-EPI 
equation-determined eGFR: CKD stage 3, eGFR 30–59 ml/min/1.73 m2; CKD stage 4, 
eGFR 15–29 ml/min/1.73 m2. We further categorized stage 3 into CKD stage 3a (eGFR 45–
59 ml/min/1.73 m2) and stage 3b (eGFR 30–44 ml/min/1.73 m2). To be comprehensive and 
reflect clinical practice, patients who had urine dipstick measurements, urine albumin-
creatinine ratio, urine protein-creatinine ratio and 24 hour urine studies were included to 
assess whether they had proteinuria. The following cut-offs were considered in determining 
whether someone had proteinuria: presence of ≥1+ proteinuria in dipstick studies, >30 mg/g 
in those who had urine albumin-creatinine ratio and urine protein-creatinine ratio studies and 
>30 mg proteinuria in 24 hour studies. Urine dipstick studies were performed using 
Multistix reagent strips (Siemens). Urine albumin was measured by immunoturbidimetric 
assay with antigen excess check on the Roche Modular platform in our laboratory. Urine 
creatinine was measured using a multistep enzymatic procedure that produces a quinone 
imine chromogen on the Roche Modular platform.
Serum alkaline phosphatase—ALP was measured using a colorimetric assay in 
accordance with a standardized method (Roche Modular Analyzer). Only outpatient 
laboratory measures were included in this analysis. For each patient, ALP level measured 
between the first and second eGFR <60 ml/min/1.73 m2 was used for the analysis. When 
multiple measures per patient were available, the one closest to second eGFR <60 ml/min/
1.73 m2 was selected.
Comorbid conditions and laboratory parameters—Demographic details were 
extracted from the EHR. Diabetes mellitus, hypertension, coronary artery disease, and other 
comorbid conditions were defined using pre-specified criteria and validated in a previous 
publication. ALP levels and other relevant outpatient laboratory details were obtained from 
our electronic laboratory records.
Outcome measures—The primary outcomes of interest, all-cause mortality and ESRD, 
were ascertained from our EHR and linkage of our CKD registry with the Social Security 
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Death Index and US Renal Data Services (USRDS). Patients were followed up from their 
date of inclusion in the registry (date of second qualifying eGFR) until September 15, 2009.
Statistical Analysis
CKD patients with and without ALP were compared on their baseline characteristics using 
Chi-square tests for categorical variables and t-tests or Wilcoxon rank-sum tests for 
continuous variables. CKD patients with measured outpatient ALP values were classified 
into quartiles: quartile 1, <66 U/L; Q2, 66–81 U/L; Q3, 82–101 U/L; and Q4, ≥102 U/L. 
Associations of the baseline characteristics and these four groups were assessed using 
Cochran-Armitage trend test for binary variables, Chi-square test for categorical variables 
with 3 levels or more, and ANOVA tests or Kruskal-Wallis tests for continuous variables.
To evaluate whether survival and ESRD among persons with CKD stages 3–4 was 
associated with ALP, we used Kaplan-Meier plots and log-rank tests with second eGFR <60 
ml/min/1.73 m2 as the time of origin. Progression to ESRD and pre-ESRD death are 
competing events; therefore we fitted cumulative incidence functions that adjust for 
competing risks and compared these results to the traditional cause-specific analysis. In 
addition, a separate analysis that included all deaths (both before and after ESRD) was also 
conducted. We used Cox proportional hazards models to assess the association between 
ALP and mortality and ESRD while adjusting for other covariates. Covariates were chosen a 
priori based on factors previously shown or thought to be related to both ALP and mortality. 
These include age, gender, race, body mass index (BMI), eGFR, diabetes, hypertension, 
hyperlipidemia, use of statins, malignancy, coronary artery disease, cerebrovascular disease, 
use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, heart failure, 
smoking, serum albumin, hemoglobin, bicarbonate, aspartate aminotransferase (AST), 
alanine transaminase (ALT), bilirubin and calcium. The missing covariate data among the 
28,678 patients is as follows: BMI, 1167 (4%); smoking, 3731 (13%); bicarbonate, 51 
(<0.5%); AST, 284 (1%); ALT, 224 (0.8%); bilirubin, 301 (1%); calcium, 52 (<0.5%); 
serum albumin, 296 (1%); and hemoglobin, 2063 (7%). We used multiple imputation (SAS 
“PROC MI”) with the Markov Chain Monte Carlo method and a single chain to impute 5 
datasets with complete covariate data. All Cox models were performed on each of the 5 
imputed datasets and the parameter estimates and standard errors were combined using SAS 
“MIANALYZE”.
The relationship between ALP and each outcome was evaluated 2 ways: with continuous 
ALP, and with ALP quartiles. We tested the interaction between eGFR and continuous ALP 
and stratified the associations by CKD stages. We did not adjust for proteinuria or 
phosphorus in our main models because we only had data in approximately 50% and 20% of 
the sample, respectively. However, we did sensitivity analyses fitting cox models with 
continuous ALP as described above and adjusting for proteinuria and serum phosphorus in 
separate analyses. We also did an additional sensitivity analysis that included only patients 
with ALP within the normal range (<149 U/L). All sensitivity analyses were also done on 
the 5 imputed datasets and the results combined using MIANALYZE.
All data analyses were conducted using Unix SAS version 9.2 (SAS Institute Inc, Cary, NC) 
and R statistical software version 2.12.2 (R Foundation for Statistical Computing, Vienna, 
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Austria). The “cmprsk” package was used for competing risk analysis. The CKD registry 
and this study were approved by the Cleveland Clinic Institutional Review Board.
Results
Baseline Patient Characteristics
We included 28,678 patients who had an ALP level between the first and second eGFR <60 
ml/min/1.73 m2 (Figure 1). Mean age of the study population was 72 ±12 (standard 
deviation) years with 54% being females and 12% African Americans. The majority of 
patients were either overweight (35%) or obese (35%). There was a statistically significant 
difference among the groups (based on the quartiles of ALP) in the prevalence of 
hypertension, congestive heart failure, use of angiotensin-converting enzyme inhibitors/
angiotensin receptor blockers, use of statins, hemoglobin, hyperlipidemia, and bicarbonate 
levels (p<0.001) (Table 1). Liver function tests such as AST, ALT, serum albumin and 
bilirubin were also significantly different, but the mean values for the entire cohort were all 
within the normal laboratory values. There was a progressive increase in PTH values from 
the lowest to highest quartiles of ALP, but a large number of patients were missing PTH 
results (p<0.001). There was no significant difference between the groups in the prevalence 
of coronary artery disease, and cerebrovascular disease (Table 1).
The proportion of missing data was similar across quartiles for all variables with missing 
data except for the following variables: hemoglobin, 8%, 8%, 7%, and 5%; proteinuria, 
50%, 50%, 52%, and 51%; phosphorus, 82%, 83%, 82%, and 74%; and iPTH, 90%, 91%, 
90%, and 87% all for quartiles 1–4, respectively. Patients with and without ALP levels 
measured were significantly different on all variables compared except for hemoglobin, 
though some of the absolute differences were small (Table 1).
ALP, ESRD, and All-Cause Mortality
After a median follow up of 2.2 years, 588 patients developed ESRD, while 4,755 died 
before reaching ESRD. There were 191 patients who developed ESRD and later died. Both 
the Kaplan-Meier and competing risk analyses showed a significant difference in overall 
mortality and ESRD among those with different ALP levels (p<0.001, Figure 2) and the 
results were similar in both analytical approaches.
ALP Quartiles
After adjusting for demographics, comorbid conditions, use of angiotensin-converting 
enzyme inhibitors/angiotensin receptor blockers, use of statins, serum albumin, hemoglobin, 
bicarbonate, eGFR, AST, ALT, bilirubin and calcium, there was a graded increase in the 
hazard for death in each quartile when compared to the reference (Table 2). Results were 
similar for overall death (pre and post-ESRD, data not shown). Even though there was a 
graded increase in the risk for ESRD with higher quartiles of ALP, the associations between 
ALP and ESRD was statistically significant only for those with ALP >102 U/L (quartile 4) 
(Table 2).
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The associations between ALP and death and ALP and ESRD were similar when examined 
as a continuous variable (Table 2). In the multivariate adjusted analysis, each standard 
deviation higher ALP (42.7 U/L) was associated with a 16% increased hazard for death and 
15% increased hazard for ESRD (Table 2). Results were similar for overall death (pre and 
post-ESRD, data not shown). We found a significant interaction between eGFR and ALP on 
mortality, and when stratifying based on CKD stage, we found that the hazardous effect of 
ALP was stronger at higher levels of eGFR (Figure 3). We did not find a significant 
interaction between eGFR and ALP on ESRD.
Sensitivity Analysis
When the analysis was restricted to those who had ALP levels within the normal range 
(<149 U/L), similar results were noted (data not shown). In a subgroup analysis that 
included patients who had serum phosphorus data (n=5667), we found that while adjusting 
for serum phosphorus, each 1-standard deviation higher ALP (42.7 U/L) was associated with 
a 10% increased hazard for mortality (95% confidence interval [CI], 1.06–1.14), and a non-
significant 9% increased risk for ESRD (95%CI, 0.99–1.19). In a subgroup analysis that 
included patients with at least one urinary protein measure (n=14,116), and after adjusting 
for all covariates plus proteinuria, each standard deviation higher ALP (42.7 U/L) was 
associated with a 16% increased hazard for mortality (95%CI, 1.12–1.19), and 17% 
increased hazard (95%CI, 1.07–1.26) for ESRD.
Discussion
Historically, ALP has only been considered a surrogate of bone metabolism in patients with 
CKD and ESRD. This study, along with other recently published studies, argues against this 
widely held perception6, 7, 9. In a diverse population with CKD stages 3 and 4, we noted a 
graded increase in the risk for the composite outcome of all-cause mortality and ESRD even 
after adjusting for relevant confounding variables. Similar results were obtained when the 
analysis was restricted to those who had ALP levels within the normal ranges (< 149 U/L) 
highlighting that even high-normal values of ALP might be associated with risk for adverse 
outcomes. To our knowledge, this is the first study to demonstrate elevated ALP increases 
the risk of ESRD and confirms the associations between elevated ALP levels and mortality 
in a more heterogeneous population of patients with CKD stages 3–4 than has been reported 
previously.
Elevated ALP levels have been associated with mortality in the general population and in 
those with ESRD3, 4, 6, 7. Tonelli et al. reported a graded, independent association (27% 
increased risk) between higher levels of ALP and mortality in the general population using 
National Health and Nutrition Examination Survey (NHANES) data4. Abramowitz et al. 
reported that among patients with eGFR ≥ 60 ml/min/1.73 m2, ALP >104 U/L was 
associated with 65% higher risk for death3. The ALP levels which portrayed an increased 
risk of death in both these studies were within the normal references ranges, similar to our 
study findings pointing out the importance of monitoring those with high-normal ALP 
values. Analysis from the Dialysis Outcomes & Practice Patterns Study (DOPPS) showed a 
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25% increased risk of all-cause mortality and 38% increased risk of hospitalization in 
patients with mild to markedly elevated ALP compared to normal controls7.
Few studies have examined the associations between ALP and mortality in a non-dialysis 
dependent CKD population. Beddhu et al. reported that doubling of ALP was associated 
with a 55% increase rate in all-cause mortality in the African American Study of Kidney 
Disease and Hypertension (AASK) cohort8. There was no association noted between ALP 
and the composite of death, dialysis, or GFR event. Another study including a veteran 
population with CKD stages 1–5 reported a 17% risk of death for every 50 U/L increase in 
ALP. After multivariate adjustment, the higher (>105 U/L) and lower (<66 U/L) quartiles 
were associated with all-cause mortality and a composite of pre-dialysis mortality and 
ESRD9. Our study confirms the associations of ALP with mortality, and differs from the 
aforementioned studies because it samples a more diverse population, and reveals the 
independent associations between ALP and ESRD.
ALP is derived from various tissue origins, but is mostly concentrated in the liver, biliary 
ducts, bone, and placenta. Tissue-nonspecific alkaline phosphatase inactivates 
pyrophosphate, an endogenous inhibitor of hydroxyapatite formation, resulting in medial 
arterial vascular calcification13. Under conditions such as hypertension, aging, diabetes and 
CKD, vascular cells undergo osteoblastic differentiation, and express several bone 
associated proteins, which includes alkaline phosphatase. Subsequently, this leads to 
mineralization of the endothelium, arterial stiffening and vascular calcification thereby 
contributing to the cardiovascular disease and mortality in CKD1, 14. ALP has been shown 
to be associated with arterial calcification in the coronary, carotid, and aorta, and superficial 
femoral artery and therefore ALP has been suggested as a surrogate for arterial 
stiffening. 5, 15
We noted an independent association between higher ALP levels and ESRD. Apart from 
vascular calcification, arterial stiffness, as measured by central pressures (brachial-ankle 
pulse wave velocity) might contribute to the progression of CKD16–18. Proposed mechanism 
of renal damage from arterial stiffness include a) highly pulsatile blood pressure and flow to 
the low resistance renal vascular bed and b) defects in the filtration barrier leading to 
intraglomerular hypertension, hyperfiltration, and eventual nephrosclerosis. Beddhu et al. 
noted higher urinary protein excretion levels in those with higher ALP levels thereby 
contributing to the progression of kidney disease8. Even though similar results were seen in 
our study as well (table 1), we could not further examine the associations between ALP level 
and proteinuria in our study due to lack of adequate data, but might be examined in other 
future studies 19. Higher ALP levels have also been associated with inflammation in CKD 
which may further contribute to the progression of kidney disease explaining these observed 
associations8, 20.
The strength of our study stems from the validation of our CKD registry, large 
heterogeneous sample size, and the availability of both dialysis and mortality data that 
provided us an opportunity to do competing risk analysis. Limitations of the analysis were 
the exclusion of patients with earlier stages of CKD with eGFR ≥ 60 ml/min/1.73 m2 who 
had albuminuria and other structural abnormalities. We were unable to identify patients with 
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active liver disease which might account for markedly elevated ALP levels. However, to 
reduce confounding, we used multivariable analysis using ALT and AST and performed a 
sensitivity analysis within the reference range of ALP (0–149 U/L) which showed similar 
results. We also lacked data relating to 25-hydroxyvitamin D, parathyroid hormone, serum 
phosphorus, and proteinuria levels for the entire study population. However, our sensitivity 
analysis that included patients with available data for serum phosphorus, and proteinuria 
showed similar associations.
Bone-specific alkaline phosphatase (bALP), an isoenzyme of ALP, is a more sensitive and 
specific marker for bone histology than intact PTH and ALP alone. High serum bALP is 
associated with fracture risk and mortality in CKD and hemodialysis patients21. Few studies 
have reported that bALP is a better predictor of death than ALP in the hemodialysis 
population22. However, bALP is not routinely measured because the assay is not readily 
available and is expensive. Therefore, most large retrospective, observational studies such as 
this use ALP since it is inexpensive and frequently measured. Further, a recent analysis 
using NHANES data did not show an association between bALP and mortality in a non-
dialysis-dependent CKD population23.
In summary, elevated ALP levels are associated with an increased risk of ESRD and all 
cause mortality in patients with CKD stages 3–4. These findings, along with previous 
studies in this area, suggest that clinicians may use ALP as a risk assessment tool to identify 
patients with higher risk for mortality and/or ESRD progression. More studies are warranted 
to confirm the association of ALP with ESRD and illuminate the pathogenetic process.
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Flow chart showing how patients were selected for this analysis.
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Cumulative incidence curves for ESRD and all-cause mortality for those with different 
levels of alkaline phosphatase
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Associations of ALP with mortality based on the stage of CKD
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